STAT1 and metabolic dysfunction-associated steatotic liver disease: To conclude, HIV-infected patients with MASLD on RPV-based therapy display increased STAT1 activation in non-parenchymal cells, suggesting there is ongoing HSC inactivation and apoptosis, which reduces the progression of hepatic damage.